Disclaimer: This content is for informational and educational purposes only and should not be construed as financial or investment advice. Always do your own research and consult a licensed financial advisor before making investment decisions.

Disclosure: The author does not hold a position in RXRX.

← Back to Free Index

RXRX

Analysis as of: 2026-07-07

Recursion Pharmaceuticals, Inc.

Clinical-stage TechBio company using an AI-native discovery stack to build its own drug pipeline and partnered discovery programs.

ai automation biotech healthcare

On Yahoo Finance ...

Jump to: Summary • Analysis • Opportunity • Risk • Trends • LE Structure • Third Party Analyst Consensus

Summary

Clinical Proof Drives the Rerating

The upside case rests on converting an AI-enabled discovery engine into repeatable clinical and partnering outcomes. If that proof emerges across more than one asset, the valuation can move from cash-backed option value toward a premium platform biotech multiple.

Analysis

Thesis

Recursion's upside comes from turning a proprietary data-and-lab loop into repeatable clinical proof; if REC-4881 gets a workable regulatory path and at least one more internal program validates, the market can revalue RXRX from cash-backed option value to a scalable drug-creation engine with better partner economics.

Last Economy Alignment

Cheaper cognition helps because Recursion owns proprietary data, automated labs, and internal assets; the cap is that regulators and human outcomes still decide value capture.

Upgrade to Allocator to also access: Thesis Critique

Opportunity Outlook

Average Implied 5-Year Multiple

3.9x (from 5 most recent analyses)

Reasoning

This is a clinical-proof and mix-shift rerating case. The upside does not require software-style dominance; it requires one credible lead asset path, a second validating internal program, and more partner economics shifting from ad hoc services toward higher-value milestones, rights retention, and eventually product revenue.

Upgrade to Allocator to also access: Simplified Opportunity Explanation

Risk Assessment

Overall Risk Summary

The main risk is still translation, not invention. Recursion already has the data, compute, and lab stack, and its software commoditization exposure is modest because value capture is tied to proprietary experiments and regulated drug assets rather than seat pricing. But until multiple programs show clinically relevant outcomes and REC-4881 gets a workable FDA path, partner leverage, unit economics, and financing flexibility remain fragile.

Upgrade to Allocator to also access: Tech Maturity Risk Score, Adoption Timing Risk Score, Moat Strength Risk Score, Capital Needs Risk Score, Regulatory Risk Score, Execution Risk Score, Concentration Risk Score, Unit Economics Risk Score, Valuation Risk Score, Macro Sensitivity Risk Score

Trends

Key Changes

No material company-specific filing or press release appeared in the last 7-10 days; the thesis still hinges on 2H26 proof points.
The stock remains near the lower half of its 52-week range, so expectations still look muted rather than euphoric.
No new financing, partner milestone, or clinical disclosure has changed the runway or validation debate since the early-June conference update.

Upgrade to Builder to also access: Future Considerations

Last Economy Structure

AI Industrial Score

0.54

They own proprietary lab data, automated experiments, and drug programs, so cheaper AI makes their engine more useful rather than obsolete. The catch is that biology, regulators, and patient outcomes still decide whether that engine earns real money.

Upgrade to Reader to also access: Score Decomposition, Confidence Level

Upgrade to Allocator to also access: Obsolescence Vectors, Pricing Fragility

Upgrade to Reader to also access: Constraint Benefit Score, Obsolescence Risk Score

Third Party Analyst Consensus

12-Month Price Target

$6.64

Upgrade to Reader to also access: Bull Case, Base Case, Bear Case

Next Arc Research